Contrasting RYTHM (RYM) and Its Rivals

RYTHM (NASDAQ:RYM) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare RYTHM to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings.

Profitability

This table compares RYTHM and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
RYTHM Competitors	-2,319.23%	-223.50%	-16.98%

Institutional & Insider Ownership

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for RYTHM and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
RYTHM Competitors	7629	13676	25509	1009	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 28.58%. Given RYTHM’s competitors stronger consensus rating and higher probable upside, analysts plainly believe RYTHM has less favorable growth aspects than its competitors.

Volatility & Risk

RYTHM has a beta of 9.44, indicating that its share price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s competitors have a beta of -3.17, indicating that their average share price is 417% less volatile than the S&P 500.

Valuation & Earnings

This table compares RYTHM and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
RYTHM	$17.28 million	-$33.26 million	-2.09
RYTHM Competitors	$16.88 billion	$3.13 billion	553.70

RYTHM’s competitors have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

RYTHM competitors beat RYTHM on 9 of the 13 factors compared.

About RYTHM

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.